Vertex Pharmaceuticals VRTX New Hypercon Technology Partnership Lifts Bullish Outlook for Halozyme HALO Royalty Trajectory SMTI Sanara MedTech reports Q4 2025 lower than expected EPS posts minor share gain despite earnings miss How Vanda Pharmaceuticals VNDA returns capital to shareholders Q4 2025 EPS Beats Forecasts